The confined fluid-filled labyrinth of the human inner ear presents an opportunity for
introduction of gene therapy reagents designed to treat hearing and balance dysfunction …

Transfer of exogenous genetic material into the mammalian inner ear using viral vectors has
been characterized over the last decade. A number of different viral vectors have been …

Despite the significant impact of hearing and balance disorders on the general population
there are currently no dedicated pharmaceuticals that target the inner ear. Advances in …

Mice present an ideal model for inner ear gene therapy because their genome is being
rapidly sequenced, their generation time is relatively short, and they serve as a valuable …

Successful delivery of genes to the inner ear has been demonstrated using a variety of
vectors and animal models. As our understanding of the molecular pathophysiology of …

Animal studies on inner ear development, repair and regeneration provide understanding of
molecular pathways that can be harnessed for treating inner ear disease. Use of transgenic …

Over seventy studies have examined the potential of gene therapy in the inner ear. For the
most part, they have focused on adenoviral vectors and delivery into the cochlea. Most …

The application of gene therapy is widely expanding in research and continuously improving
in preparation for clinical applications. The inner ear is an attractive target for gene therapy …

Drug delivery through the round window membrane has become commonplace in otologic
practice and has introduced the possibility of treating sensorineural hearing loss and …

The inner ear contains many types of cell, including sensory hair cells and neurons. If these
cells are damaged, they do not regenerate. Inner ear disorders have various etiologies …